Track how companies discuss tariffs and trade policies in their earnings calls, and understand their impact across different industries and regions.
We continue to execute our best sales strategy in response to recent tariff actions.
Midway through the quarter, tariff and other government policy initiatives led to turbulence in the market and uncertainty in the marketplace.
Commercial clients are also facing increased pressure from the dynamic external environment, coming from the uncertainty related to tariffs in a more volatile macroeconomic environment.
At this point in time, we see a limited net impact on our EPS.
Altogether, based upon what we know today, we estimate the impact of all new 2025 tariffs will be approximately $250 million on an annualized basis.
we took some actions around collective staging, and that represents really the other €20 million.
If tariffs are extended to pharmaceuticals, they would not impact ARCALYST supply received from Regeneron.
Therefore, we expect the impact to Incyte Corporation of any potential tariffs on pharmaceuticals to be minimal.
We are carefully monitoring the potential direct and indirect results of higher tariffs, and we are proactively engaging with portfolio companies to mitigate the potential impact of tariffs on our portfolio.
we feel we have an opportunity to gain share in regions with meaningful manufacturing footprints.